Skip to Content

Robert S. Benjamin, MD

Present Title & Affiliation

Primary Appointment

P. H. and Fay E. Robinson Distinguished Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1968 New York University School of Medicine, New York, NY, MD
1964 Williams College, Williamstown, MA, BA, Chemistry

Postgraduate Training

1/1972 Chemotherapy, ABIM Approved Fellowship in Medical Oncology, NCI, Baltimore Cancer Research Center
1/1970 Approved Medical Residency, New York University, Bellevue Medical Center, ABIM
1/1969 Approved Straight Medical Internship, New York University, Bellevue Medical Center, ABIM

Board Certifications

1973 American Board of Internal Medicine
1973 Medical Oncology

Experience/Service

Academic Appointments

Professor and Chairman, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2000-present

Administrative Appointments/Responsibilities

Professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1993-present

Honors and Awards

2008 Nobility in Science Award from the Sarcoma Foundation of America, SARC

Selected Publications

Peer-Reviewed Original Research Articles
1. Vadhan-Raj S, Trent J, Patel S, Zhou X, Johnson MM, Araujo D, Ludwig JA, O'Roark S, Gillenwater AM, Bueso-Ramos C, El-Naggar AK, Benjamin RS. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med 153(6):358-67, 9/21/2010. PMID: 20855800.
2. Guadagnolo BA, Zagars GK, Raymond AK, Benjamin RS, Sturgis EM. Osteosarcoma of the jaw/craniofacial region: outcomes after multimodality treatment. Cancer 115(14):3262-70, 7/15/2009. e-Pub 4/20/2009. PMID: 19382187.
3. Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Meyers PA, Myers PA, Priebat DA, Reinke DK, Thomas DG, Keohan ML, Samuels BL, Baker LH. Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model. J Clin Oncol 27(19):3148-53, 7/1/2009. e-Pub 5/18/2009. PMID: 19451433.
4. Chen LL, Holden JA, Choi H, Zhu J, Wu FF, Jones KA, Ward JH, Andtbacka RH, Randall RL, Scaife CL, Hunt KK, Prieto VG, Raymond AK, Zhang W, Trent JC, Benjamin RS, Frazier ML. Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stomal tumor correlates wth the mechanism of mitotic nondisjunction and significant tumor progression. Mod Pathol 21(7):826-36, 7/2008. e-Pub 5/2008. PMID: 18488000.
5. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26(4):626-32, 2/1/2008. PMID: 18235122.
6. Benjamin RS. SARC-CTOS imaging symposium: introduction to the problem from a clinical perspective. Oncologist 13 Suppl 2:1-3, 2008. PMID: 18434630.
7. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 25(19):2755-63, 7/2007. PMID: 17602081.
8. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13):1753-9, 5/1/2007. PMID: 17470865.
9. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C. We Should Desist Using RECIST, at Least in GIST. J Clin Oncol 25(13):1760-1764, 5/1/2007. PMID: 17470866.

Last updated: 2/25/2013